Instinct Bio Technical Co. Holdings Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Tomoki Nagano
- Full Time Employees
- 2
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Address
- 89 Nexus Way, Camana Bay Grand Cayman United States of America KY1-9009
- IPO Date
- Jul 24, 2026
- CIK
- 0002072188
- Website
- instinct-biot.com
- Similar Companies
- Business
- Biotech Acquisition Company (NASDAQ: BIOT) operates as a blank check company whose sole purpose is to effect a merger, capital stock exchange, share purchase, asset acquisition, reorganization, or similar business combination with one or more businesses, primarily targeting the biotechnology sector; it currently conducts no significant operations or offers no products or services. Incorporated in 2020 and headquartered in New York, New York, the company focuses on life sciences opportunities without specified geographic operations beyond the United States. In 2022, Biotech Acquisition Company announced and later mutually terminated a proposed merger with Blade Therapeutics, Inc., a developer of therapies for fibrotic diseases, after filing a registration statement and postponing shareholder meetings amid challenging market conditions. As of late 2025, no further mergers, acquisitions, funding rounds, or strategic shifts have materialized, with the company remaining in search of a suitable target and potentially facing delisting risks.
Company News
Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia
BIOT to Launch Indonesia’s First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia’s Fastest-Growing Aesthetics Markets
BIOT to Launch Indonesia's First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia's Fastest-Growing Aesthetics Markets
Instinct Bio (Nasdaq: BIOT) Secures $150 Million Equity Funding to Advance Regenerative Medicine Platform and Strategic Growth
Relativity Acquisition Corp. SPAC and Instinct Bio Technical Co. Announce Effectiveness of Registration Statement